Targeted anti-mitotic therapies: can we improve on tubulin agents? - PubMed (original) (raw)

Review

doi: 10.1038/nrc2049.

Affiliations

• PMID: 17251917
• DOI: 10.1038/nrc2049

Review

Targeted anti-mitotic therapies: can we improve on tubulin agents?

Jeffrey R Jackson et al. Nat Rev Cancer. 2007 Feb.

Abstract

The advent of molecularly targeted drug discovery has facilitated the identification of a new generation of anti-mitotic therapies that target proteins with specific functions in mitosis. The exquisite selectivity for mitosis and the distinct ways in which these new agents interfere with mitosis provides the potential to not only overcome certain limitations of current tubulin-targeted anti-mitotic drugs, but to expand the scope of clinical efficacy that those drugs have established. The development of these new anti-mitotic drugs as targeted therapies faces significant challenges; nevertheless, these potential therapies also serve as unique tools to dissect the molecular mechanisms of the mitotic-checkpoint response.

PubMed Disclaimer

Similar articles

• Molecularly targeted therapies for malignant gliomas: advances and challenges.
  Penas-Prado M, Gilbert MR. Penas-Prado M, et al. Expert Rev Anticancer Ther. 2007 May;7(5):641-61. doi: 10.1586/14737140.7.5.641. Expert Rev Anticancer Ther. 2007. PMID: 17492929 Review.
• BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines.
  Greene LM, Campiani G, Lawler M, Williams DC, Zisterer DM. Greene LM, et al. Mol Pharmacol. 2008 Feb;73(2):419-30. doi: 10.1124/mol.107.039024. Epub 2007 Nov 8. Mol Pharmacol. 2008. PMID: 17991869
• Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.
  Bhattacharyya B, Panda D, Gupta S, Banerjee M. Bhattacharyya B, et al. Med Res Rev. 2008 Jan;28(1):155-83. doi: 10.1002/med.20097. Med Res Rev. 2008. PMID: 17464966 Review.
• Microtubules: a dynamic target in cancer therapy.
  Pasquier E, Kavallaris M. Pasquier E, et al. IUBMB Life. 2008 Mar;60(3):165-70. doi: 10.1002/iub.25. IUBMB Life. 2008. PMID: 18380008 Review.
• How do anti-mitotic drugs kill cancer cells?
  Gascoigne KE, Taylor SS. Gascoigne KE, et al. J Cell Sci. 2009 Aug 1;122(Pt 15):2579-85. doi: 10.1242/jcs.039719. J Cell Sci. 2009. PMID: 19625502 Review.

Cited by

• The yin and yang of chromosomal instability in prostate cancer.
  Carceles-Cordon M, Orme JJ, Domingo-Domenech J, Rodriguez-Bravo V. Carceles-Cordon M, et al. Nat Rev Urol. 2024 Jun;21(6):357-372. doi: 10.1038/s41585-023-00845-9. Epub 2024 Feb 2. Nat Rev Urol. 2024. PMID: 38307951 Review.
• Crosstalk between Microtubule Stabilizing Agents and Prostate Cancer.
  Chen QH. Chen QH. Cancers (Basel). 2023 Jun 23;15(13):3308. doi: 10.3390/cancers15133308. Cancers (Basel). 2023. PMID: 37444418 Free PMC article. Review.
• Identification of a Novel Gene Signature Based on Kinesin Family Members to Predict Prognosis in Glioma.
  Pan D, Fang X, Li J. Pan D, et al. Medicina (Kaunas). 2023 Feb 20;59(2):414. doi: 10.3390/medicina59020414. Medicina (Kaunas). 2023. PMID: 36837615 Free PMC article.
• Non-coding ribonucleic acid-mediated CAMSAP1 upregulation leads to poor prognosis with suppressed immune infiltration in liver hepatocellular carcinoma.
  Wang W, Zhang J, Wang Y, Xu Y, Zhang S. Wang W, et al. Front Genet. 2022 Sep 21;13:916847. doi: 10.3389/fgene.2022.916847. eCollection 2022. Front Genet. 2022. PMID: 36212130 Free PMC article.
• Bacterial extracellular vesicles-based therapeutic strategies for bone and soft tissue tumors therapy.
  Liu H, Zhang H, Han Y, Hu Y, Geng Z, Su J. Liu H, et al. Theranostics. 2022 Sep 11;12(15):6576-6594. doi: 10.7150/thno.78034. eCollection 2022. Theranostics. 2022. PMID: 36185613 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations